CARDIOGENIC SHOCK TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
The global cardiogenic shock treatment market is estimated to be valued at USD Bn 1.10 Bn in 2024 and is expected to reach USD Bn 1.78 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031. Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's need. This failure can result from conditions like heart attack, complications after heart surgery, or heart muscle infection. Without prompt treatment it can rapidly lead to organ dysfunction and death. Globally rising cases of cardiovascular diseases and increasing demand for effective management of complex cardiac conditions are the major factors anticipated to boost the growth of the cardiogenic shock treatment market worldwide in the coming years.
Market Dynamics:
The global cardiogenic shock treatment market is primarily driven by the increasing prevalence of cardiovascular diseases such as coronary artery disease, heart attacks, and heart failures. According to the World Health Organization, in June 2021, cardiovascular diseases are the leading cause of deaths globally, taking an estimate of over 17.9 million lives each year. Moreover, rising geriatric population susceptible to develop such critical cardiac conditions also supports the market growth. Various technological advancements in mechanical circulatory support devices and rapid adoption of these effective management options offer new opportunities. However, high cost associated with devices and surgical procedures hampers market penetration in low-income regions. Additionally, lack of awareness among people about early diagnosis and management options pose challenges.
Key Features of the Study:
- This report provides in-depth analysis of the global cardiogenic shock treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cardiogenic shock treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cardiogenic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiogenic shock treatment market
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on 'Cardiogenic Shock Treatment Market' - Global forecast to 2031
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
